--This is a continuation application of PCT/EP98/05113, filed August 12, 1998, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application Nos. 60/055,615 and 60/065,236, filed August 14, 1997, and November 13, 1997, respectively.--

C1

IN THE CLAIMS:

Please delete claims 6 and 7 without prejudice or disclaimer.

Please amend the claims as follows:

C2

1. (Amended Two Times) A method for *in vivo* delivery of a fusion protein into the central nervous system (CNS), comprising administering to a human or an animal a fusion protein having a first protein comprising a non-toxic, proteolytic fragment of tetanus toxin (TT) recombinantly fused to a second protein, wherein the non-toxic, proteolytic fragment of tetanus toxin comprises a fragment C and at least the 11 amino acid residues of fragment B that immediately precede the amino terminus of fragment C, and wherein said fusion protein undergoes *in vivo* retrograde axonal transport and transynaptic transport in the CNS of the human or animal.

2. (Amended) The method according to claim 1, wherein the fusion protein is administered into a muscle.

3. (Amended) The method according to claim 2, wherein the fusion protein is administered into a muscle in the vicinity of a neuromuscular junction.

5. (Amended) The method according to claim 1, wherein the fusion protein is administered into neuronal cells.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

C4

8. (Amended) The method according to claim 1, wherein the second protein is selected from the group consisting of protein SMN, BDNF (Brain-derived neurotrophic factor), NT-3 (Neurotrophin-3), NT-4/5, GDNF (Glial cell-line-derived neurotrophic factor), IGF (Insulin-like growth factor), PNI (protease nexin I), SPI3 (Serine Protease Inhibitor protein), ICE (Interleukin-1β converting enzyme), Bcl-2, GFP (green fluorescent protein), an endonuclease, an antibody, or a drug specifically directed against neurodegenerative diseases.

9. (Amended) The method according to claim 8, wherein the composition comprises a combination of at least two of said second proteins.

10. (Amended) The method according to claim 8, wherein the second protein is located upstream from the fragment of tetanus toxin.

11. (Amended) The method according to claim 8, wherein the second protein is located downstream from the fragment of tetanus toxin.

C5

31. (Amended Two Times) A method for treating a central nervous system (CNS) disease comprising:

administering to a patient in need thereof a composition comprising a fusion protein, wherein the fusion protein comprises a first protein comprising a non-toxic, proteolytic fragment of tetanus toxin (TT) recombinantly fused to a second protein, wherein the non-toxic, proteolytic fragment of tetanus toxin comprises a fragment C and at least the 11 amino acid residues of fragment B that immediately precede the amino terminus of fragment C, and wherein the fusion protein undergoes *in vivo* retrograde axonal transport and transynaptic transport when administered to the patient.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Please add the following new claims.

--32. (New) The method according to claim 8, wherein the endonuclease is I-SceI or CRE.

33. (New) The method according to claim 8, wherein the neurodegenerative disease is latero spinal amyotrophy (LSA).

34. (New) The method according to claim 31, wherein the central nervous system disease is a neurodegenerative disease or a motoneuron disease.

35. (New) The method according to claim 34, wherein the neurodegenerative disease or the motoneuron disease is amyotrophy lateral sclerosis, spinal muscular atrophy, or a neurodegenerative lysosomal storage disease.

36. (New) The method according to claim 1 or 31, wherein the fusion protein comprises an amino acid sequence comprising SEQ ID NO:16.

37. (New) The method according to claim 1 or 31, wherein the non-toxic, proteolytic fragment of tetanus toxin consists of a fragment C and the 11 amino acid residues of fragment B that immediately precede the amino terminus of fragment C.--

REMARKS

Applicants respectfully request reconsideration and further examination in view of the following remarks.

Claims 1-5 and 8-37 are pending in this application. Claims 12-30 stand withdrawn from consideration as being directed to a non-elected invention. Claims 6 and 7 have been deleted without prejudice or disclaimer.

Claims 1-5, 8-11, and 31 have been amended as discussed in further detail

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com